Cargando…

A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro

The pentameric serum IgMs are critical to immune defense and surveillance through cytotoxicity against microbes and nascent cancer cells. Ficolins, a group of oligomeric lectins with an overall structure similar to C1q and mannose-binding lectin (MBL) participate in microbe infection and apoptotic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Xiaoying, Liu, Chaoxu, Azadzoi, Kazem, Li, Cuiling, Lu, Fan, Xiang, An, Sun, Jianbin, Guo, Yanhai, Zhao, Qingchuan, Yan, Zhen, Yang, Jinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296296/
https://www.ncbi.nlm.nih.gov/pubmed/25592840
http://dx.doi.org/10.1038/srep07824
_version_ 1782352952982241280
author Lei, Xiaoying
Liu, Chaoxu
Azadzoi, Kazem
Li, Cuiling
Lu, Fan
Xiang, An
Sun, Jianbin
Guo, Yanhai
Zhao, Qingchuan
Yan, Zhen
Yang, Jinghua
author_facet Lei, Xiaoying
Liu, Chaoxu
Azadzoi, Kazem
Li, Cuiling
Lu, Fan
Xiang, An
Sun, Jianbin
Guo, Yanhai
Zhao, Qingchuan
Yan, Zhen
Yang, Jinghua
author_sort Lei, Xiaoying
collection PubMed
description The pentameric serum IgMs are critical to immune defense and surveillance through cytotoxicity against microbes and nascent cancer cells. Ficolins, a group of oligomeric lectins with an overall structure similar to C1q and mannose-binding lectin (MBL) participate in microbe infection and apoptotic cell clearance by activating the complement lectin pathway or a primitive opsonophagocytosis. It remains unknown whether serum IgMs interplay with ficolins in cancer immunosurveillance. Here we report a natural cancer killing of different types of cancer cells by sera from a healthy human population mediated by a novel IgM–H-ficolin complement activation pathway. We demonstrate for the first time that H-ficolin bound to a subset of IgMs in positive human sera and IgM–H-ficolin deposited on cancer cells to activate complement attack in cancer cells. Our data suggest that the IgM–H-ficolin -mediated complement activation pathway may be another defensive strategy for human cancer immunosurveillance.
format Online
Article
Text
id pubmed-4296296
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-42962962015-01-16 A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro Lei, Xiaoying Liu, Chaoxu Azadzoi, Kazem Li, Cuiling Lu, Fan Xiang, An Sun, Jianbin Guo, Yanhai Zhao, Qingchuan Yan, Zhen Yang, Jinghua Sci Rep Article The pentameric serum IgMs are critical to immune defense and surveillance through cytotoxicity against microbes and nascent cancer cells. Ficolins, a group of oligomeric lectins with an overall structure similar to C1q and mannose-binding lectin (MBL) participate in microbe infection and apoptotic cell clearance by activating the complement lectin pathway or a primitive opsonophagocytosis. It remains unknown whether serum IgMs interplay with ficolins in cancer immunosurveillance. Here we report a natural cancer killing of different types of cancer cells by sera from a healthy human population mediated by a novel IgM–H-ficolin complement activation pathway. We demonstrate for the first time that H-ficolin bound to a subset of IgMs in positive human sera and IgM–H-ficolin deposited on cancer cells to activate complement attack in cancer cells. Our data suggest that the IgM–H-ficolin -mediated complement activation pathway may be another defensive strategy for human cancer immunosurveillance. Nature Publishing Group 2015-01-16 /pmc/articles/PMC4296296/ /pubmed/25592840 http://dx.doi.org/10.1038/srep07824 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Article
Lei, Xiaoying
Liu, Chaoxu
Azadzoi, Kazem
Li, Cuiling
Lu, Fan
Xiang, An
Sun, Jianbin
Guo, Yanhai
Zhao, Qingchuan
Yan, Zhen
Yang, Jinghua
A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
title A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
title_full A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
title_fullStr A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
title_full_unstemmed A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
title_short A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
title_sort novel igm–h-ficolin complement pathway to attack allogenic cancer cells in vitro
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296296/
https://www.ncbi.nlm.nih.gov/pubmed/25592840
http://dx.doi.org/10.1038/srep07824
work_keys_str_mv AT leixiaoying anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT liuchaoxu anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT azadzoikazem anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT licuiling anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT lufan anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT xiangan anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT sunjianbin anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT guoyanhai anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT zhaoqingchuan anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT yanzhen anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT yangjinghua anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT leixiaoying noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT liuchaoxu noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT azadzoikazem noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT licuiling noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT lufan noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT xiangan noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT sunjianbin noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT guoyanhai noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT zhaoqingchuan noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT yanzhen noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro
AT yangjinghua noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro